Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ladenburg Thalmann Downgrades Reata Pharmaceuticals to Neutral, Raises Price Target to $172.5

Author: Benzinga Newsdesk | July 31, 2023 09:09am
Ladenburg Thalmann analyst Matthew Kaplan downgrades Reata Pharmaceuticals (NASDAQ:RETA) from Buy to Neutral and raises the price target from $122 to $172.5.

Posted In: RETA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist